For the period, Agilent reported revenue of $1.5 billion (end-April 30), an increase of 23% compared to $1.2 billion in the second quarter of 2020. The company's net income for the period was $216 million, versus $101 million in the corresponding quarter of 2020.

Company leaders said the results exceeded expectations. Agilent also acquired Resolution Bioscience this past quarter, continuing the company's investment in high-growth markets as part of its "build and buy" growth strategy.

Company leaders also said because of the second quarter's results, Agilent is raising its revenue and earnings outlook for the full year.

Agilent debuts immune cell analysis platform
Agilent Technologies has debuted its Seahorse extracellular flux (XF) HS miniplate that provides improved immune cell metabolic analysis.

Agilent offers new flow cytometers
Agilent Technologies has launched a new product offering, the Agilent NovoCyte Penteon, a flow cytometer with five lasers and up to 30 fluorescence channels.

Agilent expands molecule manufacturing capacity
Agilent Technologies said that it's expanding its Frederick, CO-based production facility to more than double its current capacity for developing the...